Related Experiment Video

Updated: Aug 12, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?

Nico Gagelmann1, Jennifer Brudno2

  • 1University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

The Lancet. Haematology
|February 1, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

706

Related Experiment Videos

Last Updated: Aug 12, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

706

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

The Lancet. Haematology·2026

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Journal of hematology & oncology·2026

PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data.

Transplantation and cellular therapy·2026

A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation.

Transplantation and cellular therapy·2026

Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival.

Bone marrow transplantation·2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

The Lancet. Haematology·2026

Beyond maximum grade: key regulatory considerations in adverse event reporting.

The Lancet. Haematology·2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

The Lancet. Haematology·2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

The Lancet. Haematology·2026

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The Lancet. Haematology·2026

Chitosan microparticle-based antibacterial nasal barrier formulation and in vivo evaluations.

Turkish journal of chemistry·2026

Bioactive compound ginkgolide B alleviates food allergy by regulating mTOR signaling pathway.

Frontiers in immunology·2026

Post-Crosslinked Hydrazidine-Functionalized Resorcinol-Formaldehyde Imprinted Polymer for Selective S-Ketorolac Recognition.

Chirality·2026

Synthetic Heparan Sulfate-like Oligosaccharides as Tools to Decipher Growth Factor Recognition.

Journal of medicinal chemistry·2026

Convergent Synthesis of a Bifunctional GPI as a Universal Platform to Access Diverse GPI and GPI-Anchored Protein Probes.

Organic letters·2026

Regio- and Stereoselective Synthesis of Deuterium-Labeled Glutamic Acids via a Tetramic Acid Derivative.

The Journal of organic chemistry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us